Lighting up biotherapeutics

点亮生物治疗学

• 批准号: 2742804
• 金额: --
• 依托单位: University of East Anglia
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2742804
• 关键词: Lighting; up; biotherapeutics

Over the last decade, several antibody-based biotherapeutics have been developed for treatment of cancer. These antibodies, often marketed as "targeted therapeutics", bind to cell surface receptors on cancer cells and direct them towards apoptosis (programmed cell death). However, the same cell surface receptors are also present on healthy cells, leading to severe side effects. If the binding of antibody to its antigen could be activated at the site of cancer cells, it would reduce the side effects of antibody-based therapeutics. The long-term goal of this project is to develop antibodies that can be activated by light at the site of cancer cells, thereby reducing the side effects of therapeutic antibodies.

在过去的十年中，已经开发了几种基于抗体的生物治疗药物来治疗癌症。这些抗体通常被称为“靶向治疗药物”，与癌细胞上的细胞表面受体结合并引导它们凋亡（程序性细胞死亡）。然而，相同的细胞表面受体也存在于健康细胞上，导致严重的副作用。如果抗体与其抗原的结合可以在癌细胞部位被激活，那么将减少基于抗体的治疗的副作用。该项目的长期目标是开发可以在癌细胞部位被光激活的抗体，从而减少治疗抗体的副作用。